10x Genomics, CHUV Partner on Single Cell Cancer Biomarker Study
10x Genomics and Lausanne University Hospital (CHUV) launched a research collaboration to advance diagnostic applications of single cell…
10x Genomics, Lausanne University Hospital Collaborate on Single-Cell Cancer Diagnostics
10x Genomics and Lausanne University Hospital have entered a multi-year research collaboration to advance diagnostic applications of single-cell…
Roche VENTANA MMR RxDx Panel Gains EU IVDR Approval for Multiple Cancers
Roche has received European Union In Vitro Diagnostic Regulation approval for several label expansions of its VENTANA MMR…
Roche brings 7-minute lung cancer shot to India
New Delhi: Roche Pharma India has launched the country’s first injectable immunotherapy for lung cancer, allowing patients to…
Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer in India
Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer in India May 14, 2026 |…
Roche launches subcutaneous lung cancer immunotherapy, cuts delivery time to 7 min
Pharma major Roche on Thursday announced the launch of the immunotherapy drug Tecentriq that can, for the first…
Roche India Launches First Under-the-Skin Lung Cancer Therapy
This new way of giving Tecentriq shows Roche’s focus on improving cancer treatment in India. The faster under-the-skin…
Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancer
Roche Pharma on Thursday launched Tecentriq (atezolizumab), the country’s first subcutaneous immunotherapy for lung cancer — an under-the-skin…
Alps Group Inc Publishes Clinical Safety, Tolerability and
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the…
Alps Group NK cell case study backs safety profile
Alps Group (NASDAQ:ALPS) published a peer-reviewed case series (Feb 2026) reporting safety and…
Pilatus Biosciences Enters Clinical Collaboration with Roche
PLT012 is Pilatus’s lead immunomodulatory candidate. It is designed to reprogramme the fibrotic and immunosuppressive tumour microenvironment (TME)…